Streetbeat News

Revenues

AG

Silver prices have surged over 6%, causing potential billion-dollar losses for five US banks with large short positions. This has raised concerns about market integrity and the impact on industries reliant on stable silver prices. Increased investor interest in precious metals is noted, with significant options activity in First Majestic Silver (NYSE:AG) indicating bullish sentiment.

Portfolio Pulse from Rounak Jain

October 24, 2024 | 1:01 pm

BKR

Analysts' ratings for Baker Hughes (NASDAQ:BKR) show a mix of bullish and bearish sentiments, with a recent upward trend in price targets. The average 12-month price target increased by 5.73% to $43.74. Baker Hughes faces revenue challenges but maintains strong profitability and financial health.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 1:01 pm

MAT

Analysts have recently evaluated Mattel (NASDAQ:MAT), with a mix of bullish and indifferent ratings. The average 12-month price target has increased to $24.00, indicating a positive outlook. Despite revenue challenges, Mattel shows strong profitability and financial performance, though it faces high debt levels.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 1:01 pm

SLM

SLM Corp, the largest student lender in the US, has received mixed analyst ratings over the past three months. Analysts have set a 12-month price target range of $24 to $27, with an average of $26. Recent ratings include downgrades and upgrades from firms like Barclays, JP Morgan, and B of A Securities. Despite revenue challenges, SLM shows strong net margin, ROE, and ROA, but faces high debt-to-equity ratio risks.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 1:01 pm

JANX

Janux Therapeutics (NASDAQ:JANX) has been analyzed by 7 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $74.0, with a high of $100.00 and a low of $42.00. Recent analyst actions include maintaining or adjusting ratings and price targets, reflecting their views on the company's market position. Janux Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth but still lags behind industry peers. The company's financial health is strong, with efficient cost management and a prudent debt strategy.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 1:00 pm

HON

NATO

PPA

Honeywell International Inc. reported mixed Q3 results with EPS beating expectations but sales missing. The company lowered its FY24 revenue outlook, causing shares to trade lower. Despite sales headwinds, Honeywell saw growth in defense, space, and building solutions. The company also revised its segment margin and cash flow outlook.

Portfolio Pulse from Lekha Gupta

October 24, 2024 | 12:58 pm

UPS

United Parcel Service (UPS) CEO announced that shippers have lowered their volume expectations for the year-end holidays. This could impact UPS's revenue and operational planning for the holiday season.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:46 pm

LADR

Ladder Capital (NYSE:LADR) reported Q3 2024 earnings per share of $0.30, beating estimates by 11.11%, but sales of $70.97M missed expectations by 16.08% and decreased 11.02% from last year.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:42 pm

CRMD

CorMedix presented new data at ASN Kidney Week 2024, analyzing hospital admissions for bloodstream infections in HD-CVC patients. The study highlighted significant hospitalization outcomes, patient demographics, and economic impacts, including high mortality rates and substantial healthcare costs.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:40 pm

PEGY

Pineapple Energy's subsidiary, SUNation, has completed foundational engineering work for a series of commercial projects totaling 8.46 MW, valued at $11 million.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:37 pm